Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Revive Therapeutics Ltd
(OP:
RVVTF
)
0.0083
-0.0006 (-6.74%)
Streaming Delayed Price
Updated: 9:30 AM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revive Therapeutics Ltd
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
March 19, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Corporate Update
March 12, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
February 01, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
January 16, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
January 10, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
December 20, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
December 18, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
November 21, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
November 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
October 17, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
October 11, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
August 22, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
July 28, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
July 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May 30, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May 12, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
May 02, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
April 18, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
↗
April 05, 2023
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...
Via
Benzinga
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
↗
April 03, 2023
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to...
Via
Benzinga
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
April 03, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment
↗
March 28, 2023
Life sciences company Revive Therapeutics Ltd.
Via
Benzinga
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
March 28, 2023
First subject enrolled and initial top-line results expected in Q3-2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
March 20, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
March 08, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
↗
February 13, 2023
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More
Via
Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
↗
February 06, 2023
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve
Via
Benzinga
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
February 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
↗
February 03, 2023
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
Via
Benzinga
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
February 03, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
